A5101746409- Sarcoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Vascular Tumors and Angiosarcomas
- Cardiac tumors and thrombi
- Management of metastatic bone disease
- Lymphoma Diagnosis and Treatment
- Musculoskeletal synovial abnormalities and treatments
- Cancer Diagnosis and Treatment
- Italian Literature and Culture
- Diverse academic and cultural studies
- Neuroblastoma Research and Treatments
- Medical Imaging and Pathology Studies
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Oral and Maxillofacial Pathology
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Surgical site infection prevention
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- RNA Research and Splicing
- Cancer, Hypoxia, and Metabolism
- Chemotherapy-related skin toxicity
- Soft tissue tumor case studies
Istituto Ortopedico Rizzoli
2015-2025
Istituto Superiore per la Protezione e la Ricerca Ambientale
2022
Endometriosis
2022
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Mario Negri Institute for Pharmacological Research
2020
Leiden University Medical Center
2019
University of Bologna
1993-2018
Université Paris-Sud
2015
Institut Gustave Roussy
2015
Fundación Instituto Valenciano de Oncología
2013
Soft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very incidence in all populations. The majority of arise from the soft (close 75%), ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered dedicated [1.Casali P.G. Abecassis N....
Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care cancer patients) database [1.Stiller C.A. Trama A. Serraino D. Descriptive epidemiology sarcomas Europe: report from RARECARE project.Eur J Cancer. 2013; 49: 684-695Abstract Full Text PDF PubMed Scopus (265) Google Scholar]. Different tumour subtypes have distinct patterns incidence, each has no more than 0.3 incident cases per 100...
To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years age with nonmetastatic osteosarcoma extremity.From March 1997 to September 2000, 182 were evaluated. Primary consisted two blocks (15 g/m2), methotrexate (12 cisplatin (120 mg/m2), and doxorubicin (75 mg/m2). Postoperatively, received cycles (90 three each ifosfamide, methotrexate, 150 Granulocyte colony-stimulating factor support was mandatory after ifosfamide/cisplatin/doxorubicin...
PURPOSE: To provide an estimate of long-term prognosis for patients with osteosarcoma the extremity treated in a single institution neoadjuvant chemotherapy and observed at least 10 years. PATIENTS AND METHODS: Patients nonmetastatic were preoperatively high-dose methotrexate, cisplatin, doxorubicin (ADM). Postoperatively, good responders (90% or more tumor necrosis) received same three drugs used before surgery, whereas poor (less than 90% ifosfamide etoposide addition to those drugs....
PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing’s sarcoma could allow the use risk-adapted therapeutic strategies treatment. PATIENTS AND METHODS: Data on 359 bone treated at a single institution between January 1979 and April 1995 were retrospectively considered. influence clinical, hematologic, therapeutic, histologic parameters event-free survival was assessed. RESULTS: By univariate analysis, following features found to be associated poor prognosis:...
Background. Neoadjuvant chemotherapy is the most accepted treatment for localized osteosarcoma. This has led to a great improvement in limb-sparing surgery and disease-free survival. Patients with good response preoperative showed higher survival rate. Current studies examine possibility of patients whose limbs could be rescued poor necrosis reduction side effects related aggressive treatments. Methods. Between September 1986 December 1989, 164 entered second neoadjuvant study conducted at...
To identify factors that influence postrelapse survival (PRS) in patients with nonmetastatic osteosarcoma of the extremity.One hundred sixty-two recurrent extremity were retrospectively reviewed. The first-line treatment included surgery primary lesion and chemotherapy methotrexate, doxorubicin, cisplatin, ifosfamide.The projected 5-year PRS rate was 28%. Patients who had complete recurrence a 39%, whereas for those did not have surgery, 0% at 3 years (P <.0001). In latter group, influenced...
PURPOSE This study was performed to assess the prognostic value of proposed histopathologic method evaluate response primary tumor preoperative chemotherapy in Ewing's sarcoma. PATIENTS AND METHODS The evaluated from specimens 118 sarcoma patients, who were preoperatively treated by alone. Responses graded I III (macroscopic viable tumor, microscopic and no cells, respectively). Follow-up data available for all with a mean follow-up duration 86 months (range, 30 158). RESULTS A statistically...
Abstract BACKGROUND In primary central high‐grade osteosarcoma, a number of distinct subtypes have been identified, but little is known about the response to chemotherapy. METHODS The authors investigated whether correlated with histologic chemotherapy in 1058 patients osteosarcoma extremities who were treated neoadjuvant over last 20 years. tumors classified as osteoblastic (70%), chondroblastic (13%), fibroblastic (9%), and telangiectatic (6%). At diagnosis, 911 had localized disease 147...
Patients with Ewing sarcoma (ES) metastases and those who relapse fare poorly receive therapies that carry significant toxicity. This phase 1/2 study was conducted to evaluate the efficacy of figitumumab in advanced ES.Patients 10 18 years old were enrolled two dose escalation cohorts (20 30 mg/Kg intravenously every 4 weeks) 1 portion study. ES or older 2 The primary objective response rate (ORR).Thirty-one patients (n = 16), osteosarcoma 11), other sarcomas 4) Dose proceeded mg/kg weeks no...
To evaluate more accurately the effectiveness of preoperative chemotherapy in treatment patients with Ewing's sarcoma, we studied histopathologically chemotherapeutic response and correlated it to oncologic outcome.Between June 1983 December 1989, 68 nonmetastatic sarcoma extremities were treated at our institute (without radiation therapy) surgery. The specimens retrospectively evaluated for areas viable tumor cells graded from I III (macroscopic, microscopic, or no residual disease,...
Abstract Background and Methods Between 1986 2001, 162 patients with extremity osteosarcoma lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed chemotherapy. Results After disappeared in 14 patients, 16 judged unresectable both our thoracic surgeons, 132 had tumors removed simultaneously. Removal was complete 123 incomplete 9. Histologically benign 32 patients. For the 100 simultaneously...
We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients nonmetastatic osteosarcoma of the extremity.Patients age ≤ 40 years randomly received same cumulative doses drugs (ADM 420 mg/m(2), MTX 120 g/m(2), CDP 600 IFO 30 g/m(2)) but different durations (arm A, 44 weeks; arm B, 34 weeks). was given postoperatively when pathologic response to MTX-CDP-ADM poor A) primary phase B). End points study...
Surgical resection with curative intent for giant cell tumor of bone (GCTB) may be associated severe morbidity. This interim analysis evaluated reduction in surgical invasiveness after denosumab treatment patients resectable GCTB.Patients primary or recurrent GCTB, whom the initially planned surgery was functional compromise morbidity, received 120 mg subcutaneously every 4 weeks (additional doses on days 8 and 15 first cycle). Planned actual GCTB-related procedures before were reported....
BackgroundTo evaluate neoadjuvant trabectedin (1.5 mg/m2 24-h i.v. infusion every 3 weeks; three to six cycles) in patients with locally advanced myoxid liposarcoma (ML) previously untreated chemotherapy or radiation.Patients and methodsPrimary efficacy end point was pathological complete response (pCR) tumoral regression rate. Objective according RECIST (v.1.0) a secondary point.ResultsThree of 23 assessable had pCR [13%; 95% confidence interval (CI), 3% 34%]. Furthermore, very good...
Identification of factors to detect chemotherapy-resistant tumours at diagnosis is a first priority for risk-adapted therapy in the oncology children and young adults, where more individualized, effective, less toxic treatments are highly desirable. In this study, we analysed miRNAs discriminating Ewing's sarcoma (EWS) patients with different clinical outcomes order identify new indicators prognosis. miRNA expression was investigated 49 primary EWSs by using Agilent human microarray v.2...